References

1. Trowsdale, J. 1993. Genomic structure and function in the MHC. Trends Genet. 9:117.
2. Lee, J.S., J. Trowsdale, P.J. Travers, J. Carey, F. Grosveld, J. Jenkins, and W.F. Bodmer. 1982. Sequence of an HLA-DR alpha-chain cDNA clone and intron-exon organization of the corresponding gene. Nature. 299:750.
3. Gorski, J., P. Rollini, E. Long, and B. Mach. 1984. Molecular organization of the HLA-SB region of the human major histocompatibility complex and evidence for two SB beta-chain genes. Proc Natl Acad Sci U S A. 81:3934.
4. Okada, K., J.M. Boss, H. Prentice, T. Spies, R. Mengler, C. Auffray, J. Lillie, D. Grossberger, and J.L. Strominger. 1985. Gene organization of DC and DX subregions of the human major histocompatibility complex. Proc.Natl.Acad.Sci.U.S.A. 82:3410.
5. Spies, T., R. Sorrentino, J.M. Boss, K. Okada, and J.L. Strominger. 1985. Structural organization of the DR subregion of the human major histocompatibility complex. Proc-Natl-Acad-Sci-U-S-A. 82:5165.
6. Shiroishi, T., N. Hanzawa, T. Sagai, M. Ishiura, T. Gojobori, M. Steinmetz, and K. Moriwaki. 1990. Recombinational hotspot specific to female meiosis in the mouse major histocompatibility complex. Immunogenetics. 31:79.
7. Tacchini-Cottier, F., W.E. Mayer, A.B. Begovich, and P.P. Jones. 1995. Inactivation of E alpha and E beta expression in inbred and wild mice by multiple distinct mutations, some of which predate speciation within Mus species. Int Immunol. 7:1459.
8. Nelson, C.A., and D.H. Fremont. 1999. Structural principles of MHC class II antigen presentation. Rev Immunogenet. 1:47.
9. Cresswell, P. 1994. Assembly, transport, and function of MHC class II molecules. Annu.Rev.Immunol. 12:259.
10. Cresswell, P. 1996. Invariant Chain Structure and MHC Class II Function. Cell. 84:505.
11. Harding, C.V. 1995. Intracellular organelles involved in antigen processing and the binding of peptides to class II MHC molecules. Semin Immunol. 7:355.
12. Villadangos, J.A., R.J. Riese, C. Peters, H.A. Chapman, and H.L. Ploegh. 1997. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J Exp Med. 186:549.
13. Riese, R.J., and H.A. Chapman. 2000. Cathepsins and compartmentalization in antigen presentation. Curr Opin Immunol. 12:107.
14. Vogt, A.B., H. Kropshofer, G. Moldenhauer, and G.J. Hammerling. 1996. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. Proc Natl Acad Sci U S A. 93:9724.
15. Kropshofer, H., S.O. Arndt, G. Moldenhauer, G.J. Hammerling, and A.B. Vogt. 1997. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. IMMUNITY. 6:293.
16. Denzin, L.K., C. Hammond, and P. Cresswell. 1996. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J Exp Med. 184:2153.
17. Ting, J.P., and J. Trowsdale. 2002. Genetic control of MHC class II expression. Cell. 109 Suppl:S21.
18. Reith, W., and B. Mach. 2001. The bare lymphocyte syndrome and the regulation of mhc expression. Annu.Rev.Immunol. 19:331.
19. Glimcher, L.H., and C.J. Kara. 1992. Sequences and factors: A guide to MHC class-II transcription. Annu.Rev.Immunol. 10:13.
20. Benoist, C., and D. Mathis. 1990. Regulation of major histocompatibility complex class II genes: X, Y and other letters of the alphabet. Ann.Rev.Immunol. 8:681.
21. Boss, J.M. 1997. Regulation of transcription of MHC class II genes. Curr.Opin.Immunol. 9:107.
22. Kisielow, P., and H. von Boehmer. 1995. Development and selection of T cells: facts and puzzles. Adv Immunol. 58:87.
23. Jameson, S.C., K.A. Hogquist, and M.J. Bevan. 1995. Positive Selection of Thymocytes. Ann.Rev.Immunol. 13:93.
24. Ting, J.P., and A.S. Baldwin. 1993. Regulation of MHC gene expression. Curr.Opin.Immunol. 5:8.
25. Masternak, K., A. Muhlethaler-Mottet, J. Villard, M. Peretti, and W. Reith. 2000. Molecular genetics of the Bare lymphocyte syndrome. Rev.Immunogenet. 2:267.
26. Waldburger, J.M., K. Masternak, A. Muhlethaler-Mottet, J. Villard, M. Peretti, S. Landmann, and W. Reith. 2000. Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression. Immunol.Rev. 178:148.
27. Mach, B., V. Steimle, E. Martinez-Soria, and W. Reith. 1996. Regulation of MHC class II genes: Lessons from a disease. Annu.Rev.Immunol. 14:301.
28. Durand, B., P. Sperisen, P. Emery, E. Barras, M. Zufferey, B. Mach, and W. Reith. 1997. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J. 16:1045.
29. Masternak, K., E. Barras, M. Zufferey, B. Conrad, G. Corthals, R. Aebersold, J.C. Sanchez, D.F. Hochstrasser, B. Mach, and W. Reith. 1998. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat.Genet. 20:273.
30. Nagarajan, U.M., P. Louis-Plence, A. DeSandro, R. Nilsen, A. Bushey, and J.M. Boss. 1999. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. Immunity. 10:153.
31. Reith, W., S. Satola, C. Herrero Sanchez, I. Amaldi, B. Lisowska-Grospierre, C. Griscelli, M.R. Hadam, and B. Mach. 1988. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein, RF-X. Cell. 53:897.
32. Steimle, V., B. Durand, E. Barras, M. Zufferey, M.R. Hadam, B. Mach, and W. Reith. 1995. A novel DNA binding regulatory factor is mutated in primary MHC class II deficiency (Bare Lymphocyte Syndrome). Genes & Dev. 9:1021.
33. Steimle, V., and B. Mach. 1995. Complementation cloning of mammalian transcriptional regulators: the example of MHC class II gene regulators. Curr.Opin.Genet.Dev. 5:646.
34. Hasegawa, S.L., and J.M. Boss. 1991. Two B cell factors bind the HLA-DRA X box region and recognize different subsets of HLA class II promoters. Nucleic Acids Res. 19:6269.
35. Moreno, C.S., P. Emery, J.E. West, B. Durand, W. Reith, B. Mach, and J.M. Boss. 1995. Purified X2 binding protein (X2BP) cooperatively binds the class II MHC X box region in the presence of purified RFX, the X box factor deficient in the bare lymphocyte syndrome. J.Immunol. 155:4313.
36. Mantovani, R. 1999. The molecular biology of the CCAAT-binding factor NF-Y. Gene. 239:15.
37. Masternak, K., A. Muhlethaler-Mottet, J. Villard, M. Zufferey, V. Steimle, and W. Reith. 2000. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 14:1156.
38. Steimle, V., L.A. Otten, M. Zufferey, and B. Mach. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency. Cell. 75:135.
39. Klein, C., B. Lisowska Grospierre, F. LeDeist, A. Fischer, and C. Griscelli. 1993. Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome. J.Pediatr. 123:921.
40. Griscelli, C., B. Lisowska-Grospierre, and B. Mach. 1993. Combined immunodeficiency with defective expression in MHC class II genes. In Immunodeficiencies. F.S. Rosen and M. Seligman, editors. Harwood Academic Publishers, Chur, Switzerland. 141.
41. Elhasid, R., and A. Etzioni. 1996. Major histocompatibility complex class II deficiency: a clinical review. Blood Rev. 10:242.
42. Touraine, J.L., G.L. Marseglia, H. Betuel, G. Souillet, and L. Gebuhrer. 1992. The bare lymphocyte syndrome. Bone Marrow Transplant. 9 Suppl 1:54.
43. Rosen, F.S., R.J. Wedgwood, M. Eibl, and e. al. 1992. Primary immunodeficiency diseases: report of a WHO scientific group. Immunodefic.Rev. 3:195.
44. Emery, P., B. Durand, B. Mach, and W. Reith. 1996. RFX proteins, a novel family of DNA binding proteins conserved in the eukaryotic kingdom. Nucl.Acids Res. 24:803.
45. Emery, P., M. Strubin, K. Hofmann, P. Bucher, B. Mach, and W. Reith. 1996. A consensus motif in the RFX DNA binding domain and binding domain mutants with altered specifity. Mol.Cell.Biol. 16:4486.
46. Gajiwala, K.S., H. Chen, F. Cornille, B.P. Roques, W. Reith, B. Mach, and S.K. Burley. 2000. Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding [In Process Citation]. Nature. 403:916.
47. DeSandro, A.M., U.M. Nagarajan, and J.M. Boss. 2000. Associations and interactions between bare lymphocyte syndrome factors. Mol.Cell.Biol. 20:6587.
48. Villard, J., M. Peretti, K. Masternak, E. Barras, G. Caretti, R. Mantovani, and W. Reith. 2000. A functionally essential domain of RFX5 mediates activation of major histocompatibility complex class II promoters by promoting cooperative binding between RFX and NF-Y. Mol.Cell Biol. 20:3364.
49. Peretti, M., J. Villard, E. Barras, M. Zufferey, and W. Reith. 2001. Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP. Mol.Cell Biol. 21:5699.
50. Louis-Plence, P., C.S. Moreno, and J.M. Boss. 1997. Formation of a regulatory factor X/X2 box-binding protein/nuclear factor-Y multiprotein complex on the conserved regulatory regions of HLA class II genes. J.Immunol. 159:3899.
51. Gönczy, P., W. Reith, E. Barras, B. Lisowska-Grospierre, C. Griscelli, M.R. Hadam, and B. Mach. 1989. Inherited Immunodeficiency with a defect in a Major Histocompatibility Complex class II promoter-binding protein differs in the chromatin structure of the HLA-DRA gene. Mol.Cell.Biol. 9:296.
52. Kara, C.J., and L.H. Glimcher. 1991. In vivo footprinting of MHC class II genes: bare promoters in the bare lymphocyte syndrome. Science. 252:709.
53. Kara, C.J., and L.H. Glimcher. 1993. Three in vivo promoter phenotypes in MHC class II deficient combined immunodeficiency. Immunogenetics. 37:227.
54. Chang, C.H., S. Guerder, S.C. Hong, W. van Ewijk, and R.A. Flavell. 1996. Mice lacking the MHC class II transactivator (CIITA) show tissue- specific impairment of MHC class II expression. Immunity. 4:167.
55. Steimle, V., C.-A. Siegrist, A. Mottet, B. Lisowska-Grospierre, and B. Mach. 1994. Regulation of MHC class II expression by Interferon-gamma mediated by the transactivator gene CIITA. Science. 265:106.
56. Silacci, P., A. Mottet, V. Steimle, W. Reith, and B. Mach. 1994. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J.Exp.Med. 180:1329.
57. Chin, K.-C., C. Mao, C. Skinner, J.L. Riley, K.L. Wright, C.S. Moreno, G.R. Stark, J.M. Boss, and J.P.-Y. Ting. 1994. Molecular analysis of G1B and G3A IFN-gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. Immunity. 1:687.
58. Chang, C.H., and R.A. Flavell. 1995. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J.Exp.Med. 181:765.
59. Morris, A.C., J.L. Riley, W.H. Fleming, and J.M. Boss. 1998. MHC class II gene silencing in trophoblast cells is caused by inhibition of CIITA expression. Am.J.Reprod.Immunol. 40:385.
60. Ramassar, V., N. Goes, M. Hobart, and P.F. Halloran. 1996. Evidence for the in vivo role of class II transactivator in basal and IFN-gamma induced class II expression in mouse tissue. Transplantation. 62:1901.
61. Harton, J.A., and J.P. Ting. 2000. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol.Cell Biol. 20:6185.
62. Sartoris, S., M.T. Valle, A.L. Barbaro, G. Tosi, T. Cestari, A. D'Agostino, A.M. Megiovanni, F. Manca, and R.S. Accolla. 1998. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity. J.Immunol. 161:814.
63. Chang, C.H., J.D. Fontes, M. Peterlin, and R.A. Flavell. 1994. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J.Exp.Med. 180:1367.
64. Sartoris, S., G. Tosi, B. De Lerma, T. Cestari, and R.S. Accolla. 1996. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells. Eur.J.Immunol. 26:2456.
65. Otten, L.A., V. Steimle, S. Bontron, and B. Mach. 1998. Quantitative control of MHC class II expression by the transactivator CIITA. Eur.J.Immunol. 28:473.
66. Beresford, G.W., and J.M. Boss. 2001. CIITA coordinates multiple histone acetylation modifications at the HLA- DRA promoter. Nat.Immunol. 2:652.
67. Bontron, S., C. Ucla, B. Mach, and V. Steimle. 1997. Efficient Repression of Endogenous Major Histocompatibility Complex Class II Expression through Dominant Negative CIITA Mutants Isolated by a Functional Selection Strategy. Mol.Cell.Biol. 17:4249.
68. Chin, K.C., G.G. Li, and J.P. Ting. 1997. Importance of acidic, proline/serine/threonine-rich, and GTP- binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants. Proc.Natl.Acad.Sci.USA. 94:2501.
69. Fontes, J.D., B. Jiang, and B.M. Peterlin. 1997. The class II trans- activator CIITA interacts with the TBP- associated factor TAF II 32. Nucleic Acids Res. 25:2522.
70. Yun, S., K. Gustafsson, and J.W. Fabre. 1997. Suppression of MHC class II expression by human class II trans- activator constructs lacking the N-terminal domain. Int Immunol. 9:1545.
71. Zhou, H., H.S. Su, X. Zhang, J. Douhan, 3rd, and L.H. Glimcher. 1997. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant. J.Immunol. 158:4741.
72. Riley, J.L., S.D. Westerheide, J.A. Price, J.A. Brown, and J.M. Boss. 1995. Activation of class II MHC genes requires both the X box and the class II transactivator (CIITA). Immunity. 2:533.
73. Zhou, H., and L.H. Glimcher. 1995. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency. Immunity. 2:545.
74. Mahanta, S.K., T. Scholl, F.C. Yang, and J.L. Strominger. 1997. Transactivation by CIITA, the type II bare lymphocyte syndrome- associated factor, requires participation of multiple regions of the TATA box binding protein. Proc.Natl.Acad.Sci.U.S.A. 94:6324.
75. Fontes, J.D., S. Kanazawa, D. Jean, and B.M. Peterlin. 1999. Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes. Mol.Cell Biol. 19:941.
76. Kanazawa, S., T. Okamoto, and B.M. Peterlin. 2000. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity. 12:61.
77. Spilianakis, C., J. Papamatheakis, and A. Kretsovali. 2000. Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major histocompatibility complex class II genes. Mol.Cell Biol. 20:8489.
78. Sisk, T.J., S. Roys, and C.H. Chang. 2001. Self-association of CIITA and its transactivation potential. Mol.Cell Biol. 21:4919.
79. Linhoff, M.W., J.A. Harton, D.E. Cressman, B.K. Martin, and J.P. Ting. 2001. Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains. Mol.Cell Biol. 21:3001.
80. Kretsovali, A., C. Spilianakis, A. Dimakopoulos, T. Makatounakis, and J. Papamatheakis. 2001. Self-association of class II transactivator correlates with its intracellular localization and transactivation. J.Biol.Chem. 276:32191.
81. Accolla, R.S., M. Jotterand-Bellomo, L. Scarpellino, A. Maffei, G. Carra, and J. Guardiola. 1986. aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression. J.Exp.Med. 164:369.
82. Muhlethaler-Mottet, A., L.A. Otten, V. Steimle, and B. Mach. 1997. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 16:2851.
83. Landmann, S., A. Muhlethaler-Mottet, L. Bernasconi, T. Suter, J.M. Waldburger, K. Masternak, J.F. Arrighi, C. Hauser, A. Fontana, and W. Reith. 2001. Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class ii transactivator (ciita) expression. J.Exp.Med. 194:379.
84. Suter, T., U. Malipiero, L. Otten, B. Ludewig, A. Muelethaler-Mottet, B. Mach, W. Reith, and A. Fontana. 2000. Dendritic cells and differential usage of the MHC class II transactivator promoters in the central nervous system in experimental autoimmune encephalitis. Eur.J.Immunol. 30:794.
85. Waldburger, J.M., T. Suter, A. Fontana, H. Acha-Orbea, and W. Reith. 2001. Selective abrogation of major histocompatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene. J.Exp.Med. 194:393.
86. Lennon, A.M., C. Ottone, G. Rigaud, L.L. Deaven, J. Longmire, M. Fellous, R. Bono, and C. Alcaide-Loridan. 1997. Isolation of a B-cell-specific promoter for the human class II transactivator. Immunogenetics. 45:266.
87. Holling, T.M., N. van der Stoep, E. Quinten, and P.J. van den Elsen. 2002. Activated Human T Cells Accomplish MHC Class II Expression Through T Cell-Specific Occupation of Class II Transactivator Promoter III. J.Immunol. 168:763.
88. Piskurich, J.F., Y. Wang, M.W. Linhoff, L.C. White, and J.P. Ting. 1998. Identification of distinct regions of 5' flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene. J.Immunol. 160:233.
89. Piskurich, J.F., K.I. Lin, Y. Lin, Y. Wang, J.P. Ting, and K. Calame. 2000. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat.Immunol. 1:526.
90. Ghosh, N., I. Gyory, G. Wright, J. Wood, and K.L. Wright. 2001. Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells. J.Biol.Chem. 276:15264.
91. Rohn, W., L.P. Tang, Y. Dong, and E.N. Benveniste. 1999. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene. J.Immunol. 162:886.
92. Dong, Y., W.M. Rohn, and E.N. Benveniste. 1999. IFN-gamma regulation of the type IV class II transactivator promoter in astrocytes. J.Immunol. 162:4731.
93. Muhlethaler-Mottet, A., W. Di Berardino, L.A. Otten, and B. Mach. 1998. Activation of the MHC class II transactivator CIITA by interferon-g requires cooperative interaction between Stat1 and USF-1. Immunity. 8:157.
94. Piskurich, J.F., M.W. Linhoff, Y. Wang, and J.P. Ting. 1999. Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta. Mol.Cell Biol. 19:431.
95. Lee, Y.J., Y. Han, H.T. Lu, V. Nguyen, H. Qin, P.H. Howe, B.A. Hocevar, J.M. Boss, R.M. Ransohoff, and E.N. Benveniste. 1997. TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J.Immunol. 158:2065.
96. Nandan, D., and N.E. Reiner. 1997. TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-gamma action. J.Immunol. 158:1095.
97. O'Keefe, G.M., V.T. Nguyen, and E.N. Benveniste. 1999. Class II transactivator and class II MHC gene expression in microglia: modulation by the cytokines TGF-beta, IL-4, IL-13 and IL-10. Eur.J.Immunol. 29:1275.
98. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y.J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu Rev Immunol. 18:767.
99. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. Nature. 392:245.
100. Hart, D.N. 1997. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 90:3245.
101. Sallusto, F., M. Cella, C. Danieli, and A. Lanzavecchia. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products [see comments]. J.Exp.Med. 182:389.
102. Garrett, W.S., L.M. Chen, R. Kroschewski, M. Ebersold, S. Turley, S. Trombetta, J.E. Galan, and I. Mellman. 2000. Developmental control of endocytosis in dendritic cells by Cdc42. Cell. 102:325.
103. Cella, M., A. Engering, V. Pinet, J. Pieters, and A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells [see comments]. Nature. 388:782.
104. Rescigno, M., S. Citterio, C. Thery, M. Rittig, D. Medaglini, G. Pozzi, S. Amigorena, and P. Ricciardi-Castagnoli. 1998. Bacteria-induced neo-biosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells. Proc Natl Acad Sci U S A. 95:5229.
105. Austyn, J.M., J.W. Kupiec-Weglinski, D.F. Hankins, and P.J. Morris. 1988. Migration patterns of dendritic cells in the mouse. Homing to T cell- dependent areas of spleen, and binding within marginal zone. J Exp Med. 167:646.
106. Sallusto, F., and A. Lanzavecchia. 2000. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev. 177:134.
107. MacAry, P.A., M. Lindsay, M.A. Scott, J.I. Craig, J.P. Luzio, and P.J. Lehner. 2001. Mobilization of MHC class I molecules from late endosomes to the cell surface following activation of CD34-derived human Langerhans cells. Proc Natl Acad Sci U S A. 98:3982.
108. Macagno, A., M. Gilliet, F. Sallusto, A. Lanzavecchia, F.O. Nestle, and M. Groettrup. 1999. Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation. Eur J Immunol. 29:4037.
109. Morel, S., F. Levy, O. Burlet-Schiltz, F. Brasseur, M. Probst-Kepper, A.L. Peitrequin, B. Monsarrat, R. Van Velthoven, J.C. Cerottini, T. Boon, J.E. Gairin, and B.J. Van den Eynde. 2000. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity. 12:107.
110. Pierre, P., and I. Mellman. 1998. Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell. 93:1135.
111. Pierre, P., S.J. Turley, E. Gatti, M. Hull, J. Meltzer, A. Mirza, K. Inaba, R.M. Steinman, and I. Mellman. 1997. Developmental regulation of MHC class II transport in mouse dendritic cells [see comments]. Nature. 388:787.
112. Inaba, K., S. Turley, T. Iyoda, F. Yamaide, S. Shimoyama, C. Reis e Sousa, R.N. Germain, I. Mellman, and R.M. Steinman. 2000. The formation of immunogenic major histocompatibility complex class II- peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med. 191:927.
113. Rescigno, M., M. Martino, C.L. Sutherland, M.R. Gold, and P. Ricciardi-Castagnoli. 1998. Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med. 188:2175.
114. Kurts, C., W.R. Heath, F.R. Carbone, J. Allison, J.F. Miller, and H. Kosaka. 1996. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med. 184:923.
115. Bevan, M.J. 1976. Minor H antigens introduced on H-2 different stimulating cells cross- react at the cytotoxic T cell level during in vivo priming. J Immunol. 117:2233.
116. Bevan, M.J. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 143:1283.
117. Turley, S.J., K. Inaba, W.S. Garrett, M. Ebersold, J. Unternaehrer, R.M. Steinman, and I. Mellman. 2000. Transport of peptide-MHC class II complexes in developing dendritic cells. Science. 288:522.
118. Snell, G.D. 1953. The genetics of transplantation. J.Natl.Cancer Inst. 14:691.
119. Benacerraf, B. 1978. A hypothesis to relate the specificity of T lymphocytes and the activity of I region-specific Ir genes in macrophages and B lymphocytes. J Immunol. 120:1809.
120. Benacerraf, B. 1981. Role of MHC gene products in immune regulation. Science. 212:1229.
121. Schwartz, R. 1985. T-lymphocyte recognition of antigen in association with the gene products of the major histocompatibility complex. Annu.Rev.Immunol. 3:237.
122. Laufer, T.M., J. DeKoning, J.S. Markowitz, D. Lo, and L.H. Glimcher. 1996. Unopposed positive selection and autoreactivity in mice expressing class II MHC only on thymic cortex. Nature. 383:81.
123. Brocker, T., M. Riedinger, and K. Karjalainen. 1997. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J.Exp.Med. 185:541.
124. Stern, L.J., J.H. Brown, T.S. Jardetzky, J.C. Gorga, R.G. Urban, J.L. Strominger, and D.C. Wiley. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 368:215.
125. Ghosh, P., M. Amaya, E. Mellins, and D.C. Wiley. 1995. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature. 378:457.
126. Kelly, A.P., J.J. Monaco, S. Cho, and J. Trowsdale. 1991. A new human HLA class II-related locus,DM. Nature. 353:571.
127. Tonnelle, C., R. Demars, and E.O. Long. 1985. DOb: A new b chain gene in HLA-D with a distinct regulation of expression. EMBO J. 4:2839.
128. Inoko, H., A. Ando, M. Kimura, and K. Tsuji. 1985. Isolation and characterization of the cDNA clone and genomic clones of a new class II antigen heavy chain, DOa. J.Immunol. 135:2156.
129. Cho, S., M. Attaya, and J.J. Monaco. 1991. New class II-like genes in the murine MHC. Nature. 353:573.
130. Karlsson, L., and P.A. Peterson. 1992. The alpha chain gene of H-2O has an unexpected location in the major histocompatibility complex. J Exp Med. 176:477.
131. 1999. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature. 401:921.
132. Bonnerot, C., M.S. Marks, P. Cosson, E.J. Robertson, E.K. Bikoff, R.N. Germain, and J.S. Bonifacino. 1994. Association with BiP and aggregation of class II MHC molecules synthesized in the absence of invariant chain. Embo J. 13:934.
133. Bikoff, E.K., L.Y. Huang, V. Episkopou, J. van Meerwijk, R.N. Germain, and E.J. Robertson. 1993. Defective major histocompatibility complex class II assembly, transport, peptide acquisition, and CD4+ T cell selection in mice lacking invariant chain expression. J Exp Med. 177:1699.
134. Roche, P.A., C.L. Teletski, E. Stang, O. Bakke, and E.O. Long. 1993. Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proc.Natl.Acad.Sci.U.S.A. 90:8581.
135. Kropshofer, H., A.B. Vogt, C. Thery, E.A. Armandola, B.C. Li, G. Moldenhauer, S. Amigorena, and G.J. Hammerling. 1998. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. Embo J. 17:2971.
136. Liljedahl, M., T. Kuwana, W.P. Fung-Leung, M.R. Jackson, P.A. Peterson, and L. Karlsson. 1996. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. Embo J. 15:4817.
137. Maecker, H.T., S.C. Todd, and S. Levy. 1997. The tetraspanin superfamily: molecular facilitators. Faseb J. 11:428.
138. Liljedahl, M., O. Winqvist, C.D. Surh, P. Wong, K. Ngo, L. Teyton, P.A. Peterson, A. Brunmark, A.Y. Rudensky, W.P. Fung-Leung, and L. Karlsson. 1998. Altered antigen presentation in mice lacking H2-O. Immunity. 8:233.
139. van Ham, M., M. van Lith, B. Lillemeier, E. Tjin, U. Gruneberg, D. Rahman, L. Pastoors, K. van Meijgaarden, C. Roucard, J. Trowsdale, T. Ottenhoff, D. Pappin, and J. Neefjes. 2000. Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)- DO. J Exp Med. 191:1127.
140. Medzhitov, R., and C.A. Janeway, Jr. 1997. Innate immunity: the virtues of a nonclonal system of recognition. Cell. 91:295.
141. Fearon, D.T., and R.M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. Science. 272:50.
142. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu Rev Immunol. 12:991.
143. Muzio, M., G. Natoli, S. Saccani, M. Levrero, and A. Mantovani. 1998. The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor- associated factor 6 (TRAF6). J Exp Med. 187:2097.
144. Brightbill, H.D., D.H. Libraty, S.R. Krutzik, R.B. Yang, J.T. Belisle, J.R. Bleharski, M. Maitland, M.V. Norgard, S.E. Plevy, S.T. Smale, P.J. Brennan, B.R. Bloom, P.J. Godowski, and R.L. Modlin. 1999. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science. 285:732.
145. Aliprantis, A.O., R.B. Yang, M.R. Mark, S. Suggett, B. Devaux, J.D. Radolf, G.R. Klimpel, P. Godowski, and A. Zychlinsky. 1999. Cell activation and apoptosis by bacterial lipoproteins through toll- like receptor-2. Science. 285:736.
146. Guermonprez, P., J. Valladeau, L. Zitvogel, C. Thery, and S. Amigorena. 2002. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 20:621.
147. Thery, C., and S. Amigorena. 2001. The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol. 13:45.
148. Slepnev, V.I., and P. De Camilli. 2000. Accessory factors in clathrin-dependent synaptic vesicle endocytosis. Nat Rev Neurosci. 1:161.
149. Jiang, W., W.J. Swiggard, C. Heufler, M. Peng, A. Mirza, R.M. Steinman, and M.C. Nussenzweig. 1995. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature. 375:151.
150. Valladeau, J., O. Ravel, C. Dezutter-Dambuyant, K. Moore, M. Kleijmeer, Y. Liu, V. Duvert-Frances, C. Vincent, D. Schmitt, J. Davoust, C. Caux, S. Lebecque, and S. Saeland. 2000. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity. 12:71.
151. Regnault, A., D. Lankar, V. Lacabanne, A. Rodriguez, C. Thery, M. Rescigno, T. Saito, S. Verbeek, C. Bonnerot, P. Ricciardi-Castagnoli, and S. Amigorena. 1999. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med. 189:371.
152. Maurer, D., E. Fiebiger, B. Reininger, C. Ebner, P. Petzelbauer, G.P. Shi, H.A. Chapman, and G. Stingl. 1998. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation. J Immunol. 161:2731.
153. Reis e Sousa, C., P.D. Stahl, and J.M. Austyn. 1993. Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med. 178:509.
154. Arnold-Schild, D., D. Hanau, D. Spehner, C. Schmid, H.G. Rammensee, H. de la Salle, and H. Schild. 1999. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol. 162:3757.
155. Binder, R.J., D.K. Han, and P.K. Srivastava. 2000. CD91: a receptor for heat shock protein gp96. Nat Immunol. 1:151.
156. Platt, N., R.P. da Silva, and S. Gordon. 1998. Recognizing death: the phagocytosis of apoptotic cells. Trends Cell Biol. 8:365.
157. Gallucci, S., and P. Matzinger. 2001. Danger signals: SOS to the immune system. Curr Opin Immunol. 13:114.
158. Medzhitov, R., and C. Janeway, Jr. 2000. Innate immunity. N Engl J Med. 343:338.
159. Cresswell, P., N. Bangia, T. Dick, and G. Diedrich. 1999. The nature of the MHC class I peptide loading complex. Immunol Rev. 172:21.
160. Norbury, C.C., B.J. Chambers, A.R. Prescott, H.G. Ljunggren, and C. Watts. 1997. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol. 27:280.
161. Albert, M.L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I- restricted CTLs. Nature. 392:86.
162. Albert, M.L., S.F. Pearce, L.M. Francisco, B. Sauter, P. Roy, R.L. Silverstein, and N. Bhardwaj. 1998. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 188:1359.
163. Bellone, M., G. Iezzi, P. Rovere, G. Galati, A. Ronchetti, M.P. Protti, J. Davoust, C. Rugarli, and A.A. Manfredi. 1997. Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol. 159:5391.
164. Yewdell, J.W., C.C. Norbury, and J.R. Bennink. 1999. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv Immunol. 73:1.
165. Rodriguez, A., A. Regnault, M. Kleijmeer, P. Ricciardi-Castagnoli, and S. Amigorena. 1999. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol. 1:362.
166. Inaba, K., J.P. Metlay, M.T. Crowley, and R.M. Steinman. 1990. Dendritic cells pulsed with protein antigens in vitro can prime antigen- specific, MHC-restricted T cells in situ. J Exp Med. 172:631.
167. Ingulli, E., A. Mondino, A. Khoruts, and M.K. Jenkins. 1997. In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J Exp Med. 185:2133.
168. Sornasse, T., V. Flamand, G. De Becker, H. Bazin, F. Tielemans, K. Thielemans, J. Urbain, O. Leo, and M. Moser. 1992. Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo. J Exp Med. 175:15.
169. Pulendran, B., J.L. Smith, M. Jenkins, M. Schoenborn, E. Maraskovsky, and C.R. Maliszewski. 1998. Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant. J Exp Med. 188:2075.
170. Inaba, K., J.W. Young, and R.M. Steinman. 1987. Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells. J Exp Med. 166:182.
171. Mehta-Damani, A., S. Markowicz, and E.G. Engleman. 1994. Generation of antigen-specific CD8+ CTLs from naive precursors. J Immunol. 153:996.
172. McKinney, E.C., and J.W. Streilein. 1989. On the extraordinary capacity of allogeneic epidermal Langerhans cells to prime cytotoxic T cells in vivo. J Immunol. 143:1560.
173. Takahashi, H., Y. Nakagawa, K. Yokomuro, and J.A. Berzofsky. 1993. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int Immunol. 5:849.
174. Specht, J.M., G. Wang, M.T. Do, J.S. Lam, R.E. Royal, M.E. Reeves, S.A. Rosenberg, and P. Hwu. 1997. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med. 186:1213.
175. Ashley, D.M., B. Faiola, S. Nair, L.P. Hale, D.D. Bigner, and E. Gilboa. 1997. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med. 186:1177.
176. Ridge, J.P., F. Di Rosa, and P. Matzinger. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T- helper and a T-killer cell. Nature. 393:474.
177. Schoenberger, S.P., R.E. Toes, E.I. van der Voort, R. Offringa, and C.J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 393:480.
178. Bennett, S.R., F.R. Carbone, F. Karamalis, R.A. Flavell, J.F. Miller, and W.R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 393:478.
179. Ludewig, B., S. Oehen, F. Barchiesi, R.A. Schwendener, H. Hengartner, and R.M. Zinkernagel. 1999. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. J Immunol. 163:1839.
180. Zufferey, R., D. Nagy, R.J. Mandel, L. Naldini, and D. Trono. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol. 15:871.
181. Naldini, L., U. Blömer, P. Gallay, D. Ory, R. Mulligan, F.H. Gage, I. Verma, and D. Trono. 1996. In vivo gene delivery and stable transduction of non dividing cells by a lentiviral vector. Science. 272:263.
182. Zufferey, R., T. Dull, R.J. Mandel, A. Bukovsky, D. Quiroz, L. Naldini, and D. Trono. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 72:9873.
183. Zufferey, R., J.E. Donello, D. Trono, and T.J. Hope. 1999. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol. 73:2886.
184. Mizushima, S., and S. Nagata. 1990. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res. 18:5322.
185. McMahon, A.P., and A. Bradley. 1990. The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain. Cell. 62:1073.
186. Torres, R.M., and R. Kühn. 1997. Laboratory protocols for conditional gene targeting. Oxford University Press, Oxford.
187. Schiestl, R.H., and R.D. Gietz. 1989. High efficiency transformation of intact yeast cells using single stranded nucleic acids as a carrier. Curr Genet. 16:339.
188. Strubin, M., J.W. Newell, and P. Matthias. 1995. OBF-1, a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with Octamer-binding proteins. Cell. 80:497.
189. Garrity, P.A., and B.J. Wold. 1992. Effects of different DNA polymerases in ligation-mediated PCR: enhanced genomic sequencing and in vivo footprinting. Proc.Natl.Acad.Sci.U.S.A. 89:1021.
190. Ghosh, N., J.F. Piskurich, G. Wright, K. Hassani, J.P. Ting, and K.L. Wright. 1999. A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes. J.Biol.Chem. 274:32342.
191. Neil, S., F. Martin, Y. Ikeda, and M. Collins. 2001. Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. J Virol. 75:5448.
192. Chinnasamy, N., D. Chinnasamy, J.F. Toso, R. Lapointe, F. Candotti, R.A. Morgan, and P. Hwu. 2000. Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors. Hum Gene Ther. 11:1901.
193. Dyall, J., J.B. Latouche, S. Schnell, and M. Sadelain. 2001. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood. 97:114.
194. Salmon, P., V. Kindler, O. Ducrey, B. Chapuis, R.H. Zubler, and D. Trono. 2000. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood. 96:3392.
195. Pai, R.K., D. Askew, W.H. Boom, and C.V. Harding. 2002. Regulation of Class II MHC Expression in APCs: Roles of Types I, III, and IV Class II Transactivator. J Immunol. 169:1326.
196. Rajewsky, K., H. Gu, R. Kuhn, U.A. Betz, W. Muller, J. Roes, and F. Schwenk. 1996. Conditional gene targeting. J.Clin.Invest. 98:600.
197. Kuhn, R., and F. Schwenk. 1997. Advances in gene targeting methods. Curr Opin Immunol. 9:183.
198. Clark, A.J., M. Iwobi, W. Cui, M. Crompton, G. Harold, S. Hobbs, T. Kamalati, R. Knox, C. Neil, F. Yull, and B. Gusterson. 1997. Selective cell ablation in transgenic mice expression E. coli nitroreductase. Gene Ther. 4:101.
199. Nolan, G.P., S. Fiering, J.F. Nicolas, and L.A. Herzenberg. 1988. Fluorescence-activated cell analysis and sorting of viable mammalian cells based on beta-D-galactosidase activity after transduction of Escherichia coli lacZ. Proc Natl Acad Sci U S A. 85:2603.
200. Nickerson, K., T.J. Sisk, N. Inohara, C.S. Yee, J. Kennell, M.C. Cho, P.J. Yannie, G. Nunez, and C.H. Chang. 2001. Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity. J.Biol.Chem. 276:19089.
201. Morinaga, N., S.C. Tsai, J. Moss, and M. Vaughan. 1996. Isolation of a brefeldin A-inhibited guanine nucleotide-exchange protein for ADP ribosylation factor (ARF) 1 and ARF3 that contains a Sec7-like domain. Proc Natl Acad Sci U S A. 93:12856.
202. Togawa, A., N. Morinaga, M. Ogasawara, J. Moss, and M. Vaughan. 1999. Purification and cloning of a brefeldin A-inhibited guanine nucleotide- exchange protein for ADP-ribosylation factors. J Biol Chem. 274:12308.
203. Mansour, S.J., J. Skaug, X.H. Zhao, J. Giordano, S.W. Scherer, and P. Melancon. 1999. p200 ARF-GEP1: a Golgi-localized guanine nucleotide exchange protein whose Sec7 domain is targeted by the drug brefeldin A. Proc Natl Acad Sci U S A. 96:7968.
204. Bedford, M.T., D.C. Chan, and P. Leder. 1997. FBP WW domains and the Abl SH3 domain bind to a specific class of proline-rich ligands. Embo J. 16:2376.
205. Jackson, C.L., and J.E. Casanova. 2000. Turning on ARF: the Sec7 family of guanine-nucleotide-exchange factors. Trends Cell Biol. 10:60.
206. Sudol, M., K. Sliwa, and T. Russo. 2001. Functions of WW domains in the nucleus. FEBS Lett. 490:190.
207. Vremec, D., J. Pooley, H. Hochrein, L. Wu, and K. Shortman. 2000. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol. 164:2978.
208. Moser, M., and K.M. Murphy. 2000. Dendritic cell regulation of TH1-TH2 development. Nat Immunol. 1:199.
209. Maldonado-Lopez, R., T. De Smedt, P. Michel, J. Godfroid, B. Pajak, C. Heirman, K. Thielemans, O. Leo, J. Urbain, and M. Moser. 1999. CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med. 189:587.
210. Pulendran, B., J.L. Smith, G. Caspary, K. Brasel, D. Pettit, E. Maraskovsky, and C.R. Maliszewski. 1999. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A. 96:1036.
211. Fazekas de St Groth, B. 1998. The evolution of self-tolerance: a new cell arises to meet the challenge of self-reactivity. Immunol Today. 19:448.
212. Menges, M., S. Rossner, C. Voigtlander, H. Schindler, N.A. Kukutsch, C. Bogdan, K. Erb, G. Schuler, and M.B. Lutz. 2002. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med. 195:15.
213. Legge, K.L., R.K. Gregg, R. Maldonado-Lopez, L. Li, J.C. Caprio, M. Moser, and H. Zaghouani. 2002. On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J Exp Med. 196:217.
214. Yang, J.S., L.Y. Xu, Y.M. Huang, P.H. Van Der Meide, H. Link, and B.G. Xiao. 2000. Adherent dendritic cells expressing high levels of interleukin-10 and low levels of interleukin-12 induce antigen-specific tolerance to experimental autoimmune encephalomyelitis. Immunology. 101:397.
215. Allfrey, V.G., R. Faulkner, and A.E. Mirsky. 1964. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci U S A. 51:786.
216. Roth, S.Y., J.M. Denu, and C.D. Allis. 2001. Histone acetyltransferases. Annu.Rev.Biochem. 70:81.
217. Vogelauer, M., J. Wu, N. Suka, and M. Grunstein. 2000. Global histone acetylation and deacetylation in yeast. Nature. 408:495.
218. Reid, J.L., V.R. Iyer, P.O. Brown, and K. Struhl. 2000. Coordinate regulation of yeast ribosomal protein genes is associated with targeted recruitment of Esa1 histone acetylase. Mol Cell. 6:1297.
219. Kuo, M.H., E. vom Baur, K. Struhl, and C.D. Allis. 2000. Gcn4 activator targets Gcn5 histone acetyltransferase to specific promoters independently of transcription. Mol Cell. 6:1309.
220. Khochbin, S., A. Verdel, C. Lemercier, and D. Seigneurin-Berny. 2001. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev. 11:162.
221. Tse, C., T. Sera, A.P. Wolffe, and J.C. Hansen. 1998. Disruption of higher-order folding by core histone acetylation dramatically enhances transcription of nucleosomal arrays by RNA polymerase III. Mol Cell Biol. 18:4629.
222. Lee, D.Y., J.J. Hayes, D. Pruss, and A.P. Wolffe. 1993. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell. 72:73.
223. Anderson, J.D., P.T. Lowary, and J. Widom. 2001. Effects of histone acetylation on the equilibrium accessibility of nucleosomal DNA target sites. J Mol Biol. 307:977.
224. Sewack, G.F., T.W. Ellis, and U. Hansen. 2001. Binding of TATA binding protein to a naturally positioned nucleosome is facilitated by histone acetylation. Mol Cell Biol. 21:1404.
225. Robyr, D., Y. Suka, I. Xenarios, S.K. Kurdistani, A. Wang, N. Suka, and M. Grunstein. 2002. Microarray deacetylation maps determine genome-wide functions for yeast histone deacetylases. Cell. 109:437.
226. Strahl, B.D., R. Ohba, R.G. Cook, and C.D. Allis. 1999. Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena. Proc Natl Acad Sci U S A. 96:14967.
227. Bauer, U.M., S. Daujat, S.J. Nielsen, K. Nightingale, and T. Kouzarides. 2002. Methylation at arginine 17 of histone H3 is linked to gene activation. EMBO Rep. 3:39.
228. Rea, S., F. Eisenhaber, D. O'Carroll, B.D. Strahl, Z.W. Sun, M. Schmid, S. Opravil, K. Mechtler, C.P. Ponting, C.D. Allis, and T. Jenuwein. 2000. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature. 406:593.
229. Turner, B.M. 2000. Histone acetylation and an epigenetic code. Bioessays. 22:836.
230. Strahl, B.D., and C.D. Allis. 2000. The language of covalent histone modifications. Nature. 403:41.
231. Paglia, P., G. Girolomoni, F. Robbiati, F. Granucci, and P. Ricciardi Castagnoli. 1993. Immortalized dendritic cell line fully competent in antigen presentation initiates primary T cell responses in vivo. J.Exp.Med. 178:1893.
232. Lutz, M.B., F. Granucci, C. Winzler, G. Marconi, P. Paglia, M. Foti, C.U. Assmann, L. Cairns, M. Rescigno, and P. Ricciardi-Castagnoli. 1994. Retroviral immortalization of phagocytic and dendritic cell clones as a tool to investigate functional heterogeneity. J.Immunol.Methods. 174:269.
233. Girolomoni, G., M.B. Lutz, S. Pastore, C.U. Assmann, A. Cavani, and P. Ricciardi-Castagnoli. 1995. Establishment of a cell line with features of early dendritic cell precursors from fetal mouse skin. Eur.J.Immunol. 25:2163.
234. Winzler, C., P. Rovere, M. Rescigno, F. Granucci, G. Penna, L. Adorini, V.S. Zimmermann, J. Davoust, and P. Ricciardi-Castagnoli. 1997. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J.Exp.Med.%20;185:317.
235. Hamm, A., N. Krott, I. Breibach, R. Blindt, and A.K. Bosserhoff. 2002. Efficient transfection method for primary cells. Tissue Eng. 8:235.

References

Abbreviations